Management of Hyperkalemia in CKD

Introduction to Hyperkalemia Management

The American College of Cardiology recommends initiating immediate dietary potassium restriction to <3 g/day and reviewing RAAS inhibitors for patients with CKD and a potassium level of 5.9 mEq/L, with consideration of starting a newer potassium binder to maintain cardioprotective medications while achieving target potassium of 4.0-5.0 mEq/L 1, 2

The National Kidney Foundation suggests obtaining an ECG immediately to assess for hyperkalemia-related changes, including peaked T waves, widened QRS, or PR prolongation, as these indicate cardiac membrane instability requiring urgent intervention 1, 2
Patients with CKD stage 4-5 have a broader optimal potassium range (3.3-5.5 mEq/L), but 5.9 mEq/L still requires intervention to reduce mortality risk 1
The presence of heart failure, diabetes, or concurrent RAAS inhibitor use dramatically increases mortality risk at this potassium level 1, 2

The American Heart Association recommends limiting dietary potassium to <3 g/day (approximately 77 mEq/day) by restricting high-potassium foods: bananas, oranges, potatoes, tomatoes, processed foods, and salt substitutes 1, 2
Refer to a renal dietitian for culturally appropriate dietary counseling, as dietary modification alone may be sufficient for mild cases 1, 2

The European Society of Cardiology suggests that if on mineralocorticoid receptor antagonists (MRAs), halve the dose immediately when potassium >5.5 mEq/L (e.g., reduce spironolactone from 50mg to 25mg daily) 1, 2
Discontinue NSAIDs and COX-2 inhibitors immediately, as these cause sodium retention, worsen renal function, and dramatically increase hyperkalemia risk 1, 3

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend patiromer (Veltassa) as the preferred first-line agent for chronic hyperkalemia in CKD patients requiring continued RAAS inhibitor therapy 1
Sodium zirconium cyclosilicate (ZS-9/Lokelma) is an alternative with faster onset (~1 hour) 1, 3

The American College of Cardiology recommends rechecking potassium and renal function within 72 hours to 1 week after initiating dietary restriction and medication adjustments 1, 2
Continue weekly monitoring during dose titration phase until potassium stabilizes in target range of 4.0-5.0 mEq/L 1, 3, 2

The National Kidney Foundation suggests maintaining serum potassium between 4.0-5.0 mEq/L to minimize mortality risk in CKD patients 1, 3, 2

The European Society of Cardiology recommends continuing RAAS inhibitors whenever possible in CKD patients with hyperkalemia, as these medications slow CKD progression and improve cardiovascular outcomes 1, 3
The availability of newer potassium binders (patiromer, ZS-9) enables optimization of RAAS inhibitor therapy in more patients with hyperkalemia 1, 3

Plasma potassium concentrations are typically 0.1-0.4 mEq/L lower than serum levels due to platelet potassium release during coagulation, and pseudohyperkalemia can occur due to hemolysis during phlebotomy, as noted by the Mayo Clinic Proceedings 4

The American Journal of Kidney Diseases recommends restricting dietary potassium to <3 g/day (approximately 77 mEq/day) by eliminating high-potassium foods, and also eliminating all salt substitutes immediately, as these contain potassium chloride and can cause life-threatening hyperkalemia in CKD patients 5, 6
The American Journal of Kidney Diseases also suggests referring to a renal dietitian within 1 week for culturally appropriate dietary counseling, as dietary modification combined with pharmacologic management provides the most effective long-term control 5

The Mayo Clinic Proceedings notes that RAAS inhibitors (ACE inhibitors/ARBs) should not be discontinued at a potassium level of 6.1 mEq/L, as these medications slow CKD progression and improve cardiovascular outcomes 4
The American Journal of Kidney Diseases recommends reviewing all medications for potassium supplements, direct renin inhibitors, verapamil, and mannitol, as these require increased monitoring or discontinuation 5

The Mayo Clinic Proceedings advises against using sodium polystyrene sulfonate (Kayexalate) due to its limited efficacy data, unpredictable potassium-lowering effects, and serious gastrointestinal adverse effects, and instead recommends using newer potassium binders such as patiromer or sodium zirconium cyclosilicate 4

The Mayo Clinic Proceedings warns against discontinuing RAAS inhibitors reflexively at a potassium level of 6.1 mEq/L, as this can accelerate CKD progression and increase cardiovascular mortality, and instead recommends only considering temporary discontinuation or dose reduction if potassium exceeds 6.5 mEq/L 4